Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation.

Authors:
Lijiang Song
Lijiang Song
University of Warwick
United Kingdom
Prof. Dominik R Haudenschild, Ph.D.
Prof. Dominik R Haudenschild, Ph.D.
University of California Davis Medical Center
Professor
Arthritis Research
Sacramento, CA | United States
Shunwu Fan
Shunwu Fan
Sir Run Run Shaw Hospital
China

Front Pharmacol 2018 3;9:174. Epub 2018 May 3.

Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Bone resorption and homeostasis is carried out by osteoclasts, whose differentiation and activity are regulated by the RANK/RANKL axis. Our previous studies using a mouse model of joint injury show that joint trauma induces local inflammation followed by bone remodeling. The transcription factor cyclin-dependent kinase 9 (CDK9) is the major regulator of inflammation, as CDK9 inhibitor flavopiridol effectively suppress injury-induced inflammatory response. The objective of this study was to investigate the underlying mechanism through which flavopiridol regulates bone resorption. The effects of CDK9 inhibition, by the specific-inhibitor flavopiridol, on bone resorption were determined using two distinct and clinically relevant bone remodeling models. The first model involved titanium particle-induced acute osteolysis, and the second model was ovariectomy-induced chronic osteoporosis. The effects and mechanism of CDK9 inhibition on osteoclastogenesis were examined using culture of bone marrow macrophages (BMMs). Our results indicated that flavopiridol potently suppressed bone resorption in both bone-remodeling models. In addition, CDK9 inhibition suppressed osteoclastogenesis of BMM and reduced their expression of osteoclast-specific genes. Finally, we determined that flavopiridol suppressed RANKL signaling pathway via inhibition of p65 phosphorylation and nuclear translocation of NF-κB. Summary, CDK9 is a potential therapeutic target to prevent osteolysis and osteoporosis by flavopiridol treatment.

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2018.00174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944179PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
May 2018
15 Reads
1 Citation

Article Mentions


Provided by Crossref Event Data
twitter
Twitter: FrontPharmacol
May 12, 2018, 10:42 am EST

Publication Analysis

Top Keywords

bone resorption
16
cdk9 inhibition
12
bone
8
bone remodeling
8
flavopiridol
7
cdk9
6
acute osteolysis
4
osteolysis second
4
second model
4
response objective
4
particle-induced acute
4
model involved
4
involved titanium
4
titanium particle-induced
4
model ovariectomy-induced
4
ovariectomy-induced chronic
4
osteoclastogenesis examined
4
examined culture
4
culture bone
4
inhibition osteoclastogenesis
4

Similar Publications